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Abstract
The goal of this study was to determine whether MUC1 antibody conjugated with a fluoro-
phore could be used to visualize pancreatic cancer. Anti-MUC1 (CT2) antibody was conju-
gated with 550 nm or 650 nm fluorophores. Nude mouse were used to make subcutaneous
and orthotopic models of pancreatic cancer. Western blot and flow cytometric analysis con-
firmed the expression of MUC1 in human pancreatic cancer cell lines including BxPC-3 and
Panc-1. Immunocytochemistry with fluorophore conjugated anti-MUC1 antibody demon-
strated fluorescent areas on the membrane of Panc-1 cancer cells. After injecting the conju-
gated anti-MUC1 antibodies via the tail vein, subcutaneously transplanted Panc-1 and
BxPC-3 tumors emitted strong fluorescent signals. In the subcutaneous tumor models, the
fluorescent signal from the conjugated anti-MUC1 antibody was noted around the margin of
the tumor and space between the cells. The conjugated anti-MUC1 antibody bound the
tumor in orthotopically-transplanted Panc-1 and BxPC-3 models enabling the tumors to be
imaged. This study showed that fluorophore conjugated anti-MUC1 antibodies could visual-
ize pancreatic tumors in vitro and in vivo and may help to improve the diagnosis and treat-
ment of pancreatic cancer.
Introduction
The tumor marker CA19-9 can be detected in the serum of patients with pancreatic cancer.
However, the usefulness of CA19-9 as a diagnostic or prognostic cancer biomarker is question-
able. The sensitivity of serum CA19-9 ranges from 41 to 86% with a specificity of 33 to 100%,
which is not suitable for screening or diagnosis [1]. CA19-9 is frequently elevated in other in-
flammatory diseases and bile obstruction conditions such that its usefulness as a biomarker is
even more questionable. Better biomarkers for pancreatic cancer are needed [2].
MUC1 is a membrane-bound glycoprotein consisting of a large extracellular subunit of a 20
amino acid tandem repeat domain, a small extracellular domain subunit, a transmembrane
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domain and a cytoplasm tail [3]. MUC1 is frequently overexpressed in various cancers includ-
ing breast, ovarian, lung, and colon cancer [3,4]. It is also considered as a potential diagnostic,
prognostic, and therapeutic biomarker of pancreatic cancer. MUC1 is overexpressed in over
90% of pancreatic cancer patient tumors [5]. Strong expression of MUC1 is associated with re-
duced survival [6]. MUC1 targeted therapy has been tested in preclinical and clinical trials [7–
9]. Attempts have been made to detect MUC1 in the serum of patients and pancreatic cancer
tissue with various methods [10,11].
We have demonstrated that anti-CEA antibody conjugated with fluorophores helped to im-
prove cancer detection and enabled fluorescence-guided surgery (FGS) in pancreatic and colon
cancer mouse models which significantly improved outcome compared to standard bright-
light surgery [12–14]. It has been reported that cathepsin and claduin-4 targeted optical imag-
ing helped to detect pancreatic cancer and its precursor in mouse models [15,16].
In the present study, we determined whether anti-MUC1 antibody conjugated with a fluor-
ophore could target and visualize pancreatic cancer in vitro and in vivo models.
Materials and Methods
Pancreatic cancer cell lines
The human pancreatic cancer cell lines BxPC-3 [17] and Panc-1 [18] were maintained in
RPMI 1640 medium supplemented with 10% fetal bovine serum (Hyclone, Logan, UT), peni-
cillin/streptomycin (Gibco-BRL, Carlsbad, CA), sodium pyruvate (Gibco-BRL), sodium bicar-
bonate (Cellgro, Manassas, VA), L-glutamine (Gibco-BRL), and minimal essential medium
nonessential amino acids (Gibco-BRL). All cells were cultured at 37° C in a 5% CO2 incubator.
Construction of GFP-expressing pancreatic cancer cell line
The construction of green fluorescent protein (GFP) expressing Panc-1 cell line was done as
described previously [19]. For GFP gene transduction, 20% confluent Panc1 cells [18] were in-
cubated with a 1:1 precipitated mixture of retroviral supernatants of the PT67 packaging cells
and RPMI 1640 (Gibco-BRL, Life Technologies, Inc.) for 72 h. The cells were harvested by
trypsin/EDTA 72 h after incubation with GFP retroviral supernatants and subcultured at a
ratio of 1:15 into selective medium that contained 200 μg/ml G418. The level of G418 was in-
creased to 800 μg/ml stepwise. Clones expressing GFP were isolated with cloning cylinders
(Bel-Art Products, Pequannock, NJ) by trypsin/EDTA and were amplified and transferred by
conventional culture methods. High GFP-expression clones were then isolated in the absence
of G418 for> 10 passages to select for stable expression of GFP [20–22].
Mice
Athymic nu/nu nude mice (AntiCancer Inc., San Diego, CA), 4–6 weeks old, were used in this
study. Mice were kept in a barrier facility under HEPA filtration. Mice were fed with an auto-
claved laboratory rodent diet. All mouse surgical procedures and imaging were performed with
the animals anesthetized by intramuscular injection of 50% ketamine, 38% xylazine, and 12%
acepromazine maleate (0.02 ml). Animals received buprenorphine (0.10 mg/kg ip) immediate-
ly prior to surgery and once a day over the next 3 days to ameliorate pain. The maximum
tumor size was less than 2 cm. The condition of the animals was monitored every day. The ani-
mals were all sacrificed 2–3 weeks after surgery. CO2 inhalation was used for euthanasia. To
ensure death following CO2 asphyxiation, cervical dislocation was performed. All animal stud-
ies were approved by AntiCancer, Inc.’s Institutional Animal Care and Use Committee
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Antibody-dye conjugation
Hamster monoclonal antibodies to MUC1 (CT2; Thermo Scientific, Rockford, IL, USA) were
conjugated with DyLight 650 or 550 dyes (Thermo Scientific, Rockford, IL, USA) per manufac-
turer specifications, ensuring a minimum of at least 4:1 dye: protein ratio. Protein: dye concen-
trations were confirmed using a NanoDrop Spectrophotometer (Thermo Fisher Scientific,
Waltham, Massachusetts) [23].
Western blotting
Cell lysates were extracted in lysis buffer containing 70 mM β-glycerophosphate, 0.6 mM sodi-
um orthovanadate, 2 mMMgCl2, 1 mM ethylene glycol tetraacetic acid, 1 mM DTT (Invitro-
gen, Grand Island, NY, USA), 0.5% Triton-X100, 0.2 mM phenylmethylsulfonyl fluoride, and
1% protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA). Lysates were separated by
sodium dodecylsulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to
polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). The membranes were
blocked in 5% (w/v) non-fat dry milk and probed with antibodies. Anti-MUC1 (CT2) was
used. The immunoreactive proteins were visualized using the SuperSignal West Pico Chemilu-
minescent Substrate (Thermo Scientific, Rockford, IL, USA).
Flow cytometric analysis
Cells were grown to 80% confluence, treated with accutase solution (Sigma) for 5 minutes,
washed twice with fluorescence-activated cell sorting (FACS) buffer (2% FBS, 0.1% sodium
azide in PBS). Cells (1 × 106) were resuspended in the FACS buffer. Cells were fixed with 2%
paraformaldehyde and then blocked with 2% BSA-PBS solution for 30 min at room tempera-
ture. Cells were incubated with anti-MUC1 (CT2, 2 μg/test) for 40 min at room temperature,
and then with goat anti-Armenian hamster IgG-FITC (Santa Cruz Biotechnology, Dallas, TX,
USA) for 40 min at room temperature. After washing with FACS buffer, cells were resuspended
in FACS buffer and subjected to flow cytometry using a FACS Aria (BD Immunocytometry
Systems, Franklin Lakes, NJ). Side scatter and forward scatter profiles were used to eliminate
cell doublets.
Immunocytochemistry of live cells
Panc-1 cells (2 x 105) were cultured overnight. Anti-MUC1 (CT2) antibody conjugated with
DyLight 550 dyes was diluted to 4 μg/ml in PBS (Corning cellgro, Manassas, VA). The culture
medium from the cells was aspirated and the diluted antibody was added to the live cells. Cells
were incubated with antibody for 1 hour at room temperature. The cells were washed gently 2
times with phosphate-buffered saline after the antibody was aspirated. The cells were observed
under an FV1000 confocal microscope (Olympus, Tokyo, Japan) with white light and 559 nm
laser [24].
Immunohistochemistry
For fluorescence immunostaining on slides made from frozen tumor tissue, anti-MUC1 (CT2)
conjugated with DyLight 650 was used. The slides were incubated with 10% normal donkey
serum for 1 hour at room temperature, and incubated with the conjugated antibody at room
temperature for 1 hour at a dilution of 1:100. Tissues were dried and observed with an IV-100
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scanning laser microscope (Olympus, Tokyo, Japan) with 633 nm laser [25]. Alternate slides
from the same frozen tumor tissue were stained with hematoxylin and eosin and observed
under light microscope.
Skin flap model
Nude mice were anesthetized with the ketamine mixture via subcutaneous injection. An arc-
shaped incision was made in the abdominal skin. The subcutaneous connective tissue was sepa-
rated to free the skin flap without injuring the artery and vein. The skin flap was spread and
fixed on the flat stand. Panc-1-GFP (1 X 106 cells) in 30 μl of matrigel were sprinkled on the in-
side surface of the skin flap, and the skin was closed [26].
Subcutaneous and orthotopic tumor mouse model
To make subcutaneously transplanted pancreatic tumor models, Panc-1 and BxPC-3 human
pancreatic cancer cells (2 × 106) were injected subcutaneously into the flanks of nude mice.
When the subcutaneous tumors grew between 10 and 20 mm in diameter, they were harvested
and fragmented into small fragments. The tumor fragments were implanted orthotopically in
nude mice, as previously described [19,27–29].
Whole body imaging
In both subcutaneous and orthotopic tumor models, the mice were injected with the antibody
conjugated with fluorophore into the tail vein, and then whole body imaging was performed
using the OV100 Small Animal Imaging System (Olympus, Tokyo, Japan) after anesthesia with
the ketamine mixture described above [30]. The optimal dose for animal studies was decided
by dose of the conjugated antibody which produced images with the best tumor to background
ratio in subcutaneous tumor model.
Image analysis
All images were analyzed using Image-J (National Institutes of Health, Bethesda, Maryland)
before the process of images and compared. Image process was done with Adobe Photoshop
CS3 (Adobe Systems Inc., San Jose, California).
Results
Expression of MUC1 in pancreatic cancer cell lines
Both pancreatic cancer cell lines tested (BxPC-3 and Panc-1) had MUC1 expression observed
with Western blotting (Fig 1A). The proportion of MUC1 positive cells were 36.9% in BxPC3
and 24.4% in Panc1 pancreatic cancer cell lines, as observed with flow cytometry (Fig 1B). The
same test was repeated in each cell line at least three times. The results of all experiments
showed that anti-MUC1 (CT2) antibody could detect MUC1 on the cell membrane of pancre-
atic cancer cells in vitro.
Immunocytochemistry was also performed using anti-MUC1 (CT2) antibody conjugated
with flourophores. After incubation with the conjugated antibody without permeation, multi-
ple fluorescent dots were noted on the surface of Panc-1 cells under a fluorescence microscope
(Fig 1C). Merging with corresponding differential interference contrast microscopy confirmed
that the fluophore-conjugated antibody reacted with MUC1 on the surface of the pancreatic
cancer cells and produced fluorescence.
Targeting of Pancreatic Cancer with MUC1
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Targeting of subcutaneous pancreatic tumors with fluorescent MUC1
When BxPC-3 or Panc-1 subcutaneous tumors had reached approximately 10–20 mm in di-
ameter, the animals were each given a single 30 μg dose of DyLight 650-conjugated anti-MUC1
(CT2) via the tail vein. The mice were imaged under both brightfield and fluorescence illumi-
nation using the Olympus OV100 Small Animal Imaging System. Both Panc-1 (Fig 2A) and
BxPC-3 (data not shown) tumor showed stronger fluorescence. Fluorescence immunostaining
was performed on frozen tumor samples made from BxPC-3 and showed fluorescence on cell
membranes demonstrating the expression of MUC1 (Fig 2B).
Targeting of pancreatic cancer cells in skin flaps with fluorescent MUC1
Mice with pancreatic cancer cells growing in skin flaps were injected with anti-MUC1 (CT2)
conjugated with DyLight 550 dyes into the tail vein. Forty-eight hours after the antibody injec-
tion, the skin flap was spread again. Imaging was performed with the OV100 and FV1000. Sev-
eral colonies of cancer cells were noted on the surface of skin flap with the OV100. GFP
fluorescence signals from individual cancer cells were observed with the FV1000. At the outside
Fig 1. Characterization of pancreatic cancer cell lines. (A) Western blot analysis shows MUC1 expression in pancreatic cancer cell lines (BxPC-3 and
Panc-1). (B) Flow cytometric analysis shows the expression of MUC1 on the surface of BxPC-3 and Panc-1 cell lines. (C) Immunocytochemistry on live cells
shows multiple fluorescent dots on the surface of Panc-1 cells. Representative fluorescence images merged with corresponding DIC (differential interference
contrast) images (x60 water immersion objective on FV1000, using the 559 nm laser).
doi:10.1371/journal.pone.0122100.g001
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margin of the colony and space between the cancer cells inside of the colony, 550 nm fluores-
cence signals, which originated from the fluorophore-conjugated antibody, were observed. (Fig
3) The results demonstrated that the antibody reacted with MUC1 on the membrane of the
cancer cells in vivo.
Fig 2. Imaging of MUC1 targeting of subcutaneously-transplanted pancreatic tumors in vivo.Representative images are shown. (A) The mouse is
imaged under both white light and fluorescence illumination. The intensity of the red fluorescence signal from the Panc1 subcutaneous tumor is stronger than
background. (B) Hematoxylin and eosin staining (x200, left). Fluorescence immunostaining for MUC1 (x20 regular objective, right) of frozen tumor samples
shows fluorescence signals at the membrane of the cancer cells.
doi:10.1371/journal.pone.0122100.g002
Fig 3. Imaging of MUC1 targeting of pancreatic tumors growing on skin flaps.Representative images were obtained under white light, and 473 nm and
559 nm lasers on the OV100, and merged. GFP signal from the individual cancer cells and red fluorescent signal from the DyLight 550 fluorophore-
conjugated anti-MUC1 antibody at the outside margin of the colony and space between the cancer cells were observed.
doi:10.1371/journal.pone.0122100.g003
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Targeting of pancreatic tumors in orthotopic models with fluorescent
MUC1
Mice with tumors implanted orthotopically into the mouse pancreas were injected with
DyLight 650-conjugated anti-MUC1 (CT2) antibody with a single 30 μg dose via the tail vein
7–10 days after tumor implantation. Imaging was performed after opening the abdomen of the
mice. Intravital imaging with the OV100 detected the fluorescence signal coming from Panc1
and BxPC3 tumors (Fig 4). Tumors less than 5 mm could be detected with fluorescence imag-
ing (Fig 4). The mean ratios of fluorescence intensity between tumor and background in Panc-
1 and BxPC-3 orthotopic tumors were 6.70 and 2.39, respectively. These results confirmed that
in orthotopic tumor models, MUC1 targeted pancreatic cancer and enabled tumor detection.
Other than the tumor, fluorescence signals were detected from the skin and, bladder and intes-
tinal contents, but at lower intensity.
Fig 4. Imaging of MUC1 targeting of orthotopically-transplanted Panc-1 and BxPC-3 pancreatic tumor in vivo. Fluorescence signals from pancreatic
tumors orthotopically transplanted at the tail of the pancreas were detected. Other than the tumor, fluorescence signal was detected from the skin and,
bladder and intestinal contents but at lower intensity than the tumor. White arrows indicate pancreatic tumor.
doi:10.1371/journal.pone.0122100.g004
Targeting of Pancreatic Cancer with MUC1
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Discussion
MUC1 is a very attractive imaging biomarker for pancreatic cancer since it is overexpressed in
approximately 90% of pancreatic cancer patients [5,6]. The present results from subcutaneous
and orthotopic tumor models demonstrate that MUC1 can target and visualize pancreatic can-
cer by making it fluorescent. The results of the present study demonstrate that MUC1 is an ad-
ditional target for pancreatic cancer labeling and therapeutics delivery. MUC1 may be a useful
target to identify and treat distant metastasis of all cancer types expressing the antigen using la-
beled or therapeutic-carrying antibodies.
BxPC-3 and Panc-1 were selected based on previous studies with these cell lines for fluores-
cence-guided surgery (FGS) [13,14]. It is possible that the fraction of positive cells in the tumor
is less than that seen by flow cytometry due to steric hindrance to antibody entry into the
tumor. It is also possible that the presence of stromal cells in the tumor may decrease the per-
centage of positive cells.
The CT2 antibody is recognizing both live cancer cells as well as the cells within the tumor
in the mouse which is readily visualized by conjugation of the antibody to a fluorophore. It is
possible that in the live cell, sufficient parts of the cytoplasmic tail become accessible to the an-
tibody. As recently shown by Kumar et al, more study is needed to understand structure and
subcellular localization of MUC1 protein [31].
There have been attempts to use MUC1 as a treatment target. MUC1 targeted imaging can
guide therapeutics to the tumor [11,32,33]. Imaging for MUC1 can demonstrate whether thera-
peutic targets are present in cancer cells and predict the treatment response of MUC1-targeted
therapy [5]. In addition, fluorescence imaging targeted at MUC1 in pancreatic cancer can im-
prove tumor visualization in order to achieve complete resection during surgery. Fluorescent
guided surgery (FGS) has been shown to improve survival in mouse models with pancreatic
cancer [13,14].
In the present study, we wished to study MUC1 targeting of human pancreatic cancer with
the next goal of studying MUC1 targeting in our pancreatic cancer orthotopic xenograft
(PDOX) models [12]. Subsequent future studies will be on MUC1 targeting in spontaneous
PDAC mouse models. Formal bio-distribution studies will be done in future experiments. The
present study shows MUC1 can be used for selective tumor targeting in vivo. Based on the abil-
ity of fluorescent MUC1 antibody targeting to illuminate these tumors, we can now compare
FGS in future studies with labeled anti-CEA and anti-MUC1.
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